Global Cystic Fibrosis Therapeutics Market

Cystic Fibrosis Therapeutics Market Size, Share, Growth Analysis, By Drug Class(CFTR modulators, Mucolytics, Pancreatic enzyme supplements, and Bronchodilators), By Route of Administration(Oral drugs and Inhaled drugs), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35I2224 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 62 | Figures: 75

Cystic Fibrosis Therapeutics Market Dynamics

Global Cystic Fibrosis Therapeutics Market Drivers

Increasing Prevalence of Cystic Fibrosis

  • The primary driver of the cystic fibrosis therapeutics market is the increasing prevalence of cystic fibrosis, a genetic disorder that affects the respiratory, digestive, and reproductive systems. The disease is incurable and requires lifelong treatment, driving the demand for cystic fibrosis therapeutics.

Growing Demand for Personalized Medicine

  • The growing trend toward personalized medicine is driving the development of targeted therapies for cystic fibrosis, which can improve treatment outcomes and reduce side effects. Personalized medicine approaches are also expected to drive the growth of the cystic fibrosis therapeutics market in the coming years.

Global Cystic Fibrosis Therapeutics Market Restraints

High Cost of Cystic Fibrosis Therapies

  • The high cost of cystic fibrosis therapies, particularly new targeted therapies, is a major barrier to treatment access for many patients. This has led to concerns about the affordability of these drugs and the impact on healthcare systems.

Limited Patient Pool

  • Cystic fibrosis is a rare disease, affecting a relatively small patient population. This has limited the commercial potential of cystic fibrosis therapeutics and may impact the development of new drugs.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Cystic Fibrosis Therapeutics Market size was valued at around USD 5.30 billion in 2022 and is expected to rise from USD 6.02 billion in 2023 to reach a value of USD 16.57 Billion by 2031, at a CAGR of 13.50% over the forecast period (2024-2031).

The cystic fibrosis therapeutics market competition consists of respiratory device manufacturers as well as standalone cystic fibrosis therapeutics producers. New technical advancements, such as the use of artificial intelligence, will generate growth prospects for new market entrants. For example, NuvoAir, a Swedish health care firm, created a digital platform that allows customers to perform at-home lung function tests. Companies are battling for market share, particularly in nations with advanced technology such as the United Kingdom, Germany, and the United States. Acquisitions and cooperation amongst market participants to strengthen their position have occurred. This is projected to increase market competition over the projection period. 'Vertex Pharmaceuticals Incorporated', 'AbbVie Inc.', 'Gilead Sciences, Inc.', 'Genentech, Inc.', 'Novartis AG', 'Teva Pharmaceutical Industries Ltd.', 'Mylan N.V.', 'Perrigo Company plc', 'Pharmaxis Ltd.', 'Celtaxsys, Inc.', 'Savara Inc.', 'Kamada Ltd.', 'Chiesi Farmaceutici S.p.A.', 'Galapagos NV', 'Proteostasis Therapeutics, Inc.', 'Eloxx Pharmaceuticals, Inc.', 'Insmed Incorporated', 'Arcturus Therapeutics Holdings Inc.', 'Translate Bio, Inc.', 'Zogenix, Inc.'

The primary driver of the cystic fibrosis therapeutics market is the increasing prevalence of cystic fibrosis, a genetic disorder that affects the respiratory, digestive, and reproductive systems. The disease is incurable and requires lifelong treatment, driving the demand for cystic fibrosis therapeutics.

Growing demand for personalized medicine: As the understanding of the genetic basis of cystic fibrosis improves, there is a growing demand for personalized medicine that targets the specific mutations responsible for the disease. This trend is expected to continue in the coming years, as newer therapies are developed that target specific mutations.

Asia Pacific had the largest cystic fibrosis market share in 2022 and is further expected to continue the same during the forecast period. The number of patients within the area is increasing and the urban lifestyle becomes more popular. This, together with increased healthcare spending, will most likely drive the APAC market. Furthermore, China's cystic fibrosis market had the highest market share, while India's cystic fibrosis market is the fastest expanding in the area.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Cystic Fibrosis Therapeutics Market

Report ID: SQMIG35I2224

$5,300
BUY NOW GET FREE SAMPLE